• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.95% Nasdaq Down2.40%

    Marina Biotech, Inc. (MRNA)

    -Other OTC
    0.44 Down 0.06(12.16%) Jun 29, 4:03PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Marina Biotech, Inc.
    PO Box 1559
    Bothell, WA 98041
    United States - Map
    Phone: 425-892-4322
    Website: http://www.marinabio.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:1

    Business Summary 

    Marina Biotech, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of nucleic acid-based therapies to treat orphan diseases. The company’s therapies include small interfering RNA, microRNA (miRNA) mimics, and antagomirs, as well as antisense compounds, including messengerRNA therapeutics. Its pipeline comprise CEQ508 that is in clinical program for the treatment of Familial Adenomatous Polyposis, a precancerous syndrome; and preclinical programs in type 1 myotonic dystrophy and Duchenne’s muscular dystrophy. The company also has a strategic alliance with Rosetta Genomics, Ltd. to identify and develop miRNA -based products to diagnose and treat various neuromuscular diseases and dystrophies; and with Avecia Nitto Denko to develop, supply, and commercialize various oligonucleotides constructs using company’s conformationally restricted nucleotide technology. It has licensing agreements with Mirna Therapeutics, Inc.; ProNAi Therapeutics, Inc.; Monsanto Company; MiNA Therapeutics, Ltd.; Novartis Institutes for Biomedical Research, Inc.; Protiva Biotherapeutics Inc.; and Arcturus. The company was formerly known as MDRNA, Inc. and changed its name to Marina Biotech, Inc. in July 2010. Marina Biotech, Inc. was founded in 1983 and is based in Bothell, Washington.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Marina Biotech, Inc.

    Key Executives 
     PayExercised
    Mr. J. Michael French , 55
    Chairman, Chief Exec. Officer and Pres
    288.00K0.00
    Mr. Daniel E. Geffken M.B.A., 58
    Interim Chief Financial Officer
    136.00K0.00
    Mr. Michael V. Templin Ph.D.,
    Chief Technology Officer
    N/AN/A
    Mr. Ed Bell ,
    Director of Investor Relations
    N/AN/A
    Ms. June D. Ameen R.N., M.B.A., 59
    Sr. VP of Strategic Allances
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders